British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss, Luke Miels, has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications.The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash. Continue reading...